Prognostic and Diagnostic Value of Endocan in Kidney Diseases

Samouilidou, Elisabeth; Athanasiadou, Virginia; Grapsa, Eirini

doi:10.1155/2022/3861092

Cited by 8 publications

(6 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent data have confirmed the importance of endocan in inflammation, vascular proliferation, and neogenesis[ 22 ]. In human umbilical vein endothelial cells under intermittent hypoxia, endocan promotes the expression of the cell adhesion molecule slCAM1.…”

Section: Discussionmentioning

confidence: 91%

Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4

Xu¹,

Lu²,

Wang³

et al. 2022

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Endothelial injury and inflammation are the main pathological changes in hyperuricemic nephropathy (HN); however, they have not been assessed in patients in the early, middle, and late phases of HN. AIM To investigate endothelial injury and inflammatory conditions between patients with HN at chronic kidney disease (CKD) stages 3-4 and CKD 1-2. METHODS This study enrolled 80 patients (49 and 31 with HN at CKD stage 1-2 and 3-4, respectively) from the Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine between July 2021 and January 2022. Plasma levels of heparan sulfate, endocan, oxidized low-density lipoprotein (Ox-LDL), E-selectin, soluble intercellular adhesion molecule-1 (slCAM1), interleukin (IL)-1β, and IL-6 and urine levels of lipocalin-type prostaglandin D synthase (L-PGDS), IL-1β, and IL-6 were measured using enzyme-linked immunosorbnent assay. RESULTS Comparison between patients with HN at CKD 1-2 and those with HN at CKD 3-4 showed that age and disease course were significant factors ( P < 0.001 and P < 0.010, respectively). There were no statistical differences in sex, heart rate, body mass index, and systolic and diastolic blood pressures. The incidence of hypertension was also significant ( P = 0.03). Plasma levels of heparin sulfate ( P < 0.001), endocan ( P = 0.034), E-selectin ( P < 0.001), slCAM1 ( P < 0.001), IL-1β ( P = 0.006), and IL-6 ( P = 0.004) and the urine levels of L-PGDS ( P < 0.001), IL-1β ( P = 0.003), and IL-6 ( P < 0.001) were high in patients with HN at CKD 3-4 than in those with HN at CKD 1-2. The difference in plasma Ox-LDL levels was not significant ( P = 0.078). CONCLUSION Vascular endothelial injury and inflammation were higher in patients with HN at CKD3-4 than at CKD 1-2. Plasma heparin sulfate and slCAM1 levels are synergistic factors for CKD staging in HN.

show abstract

Section: Discussionmentioning

confidence: 91%

Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4

Xu¹,

Lu²,

Wang³

et al. 2022

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…In the literature, recent studies showed that endocan values were affected in many diseases such as kidney diseases, 38 T2DM, 39,40 preterm premature rupture of membrane, 41 preeclampsia, 42 non‐alcoholic fatty liver disease, 43 cancer, 44 periodontal disease, 45 and human obesity 46 in which vascular angiogenesis, endothelial dysfunction, and inflammation was claimed to be the underlying pathophysiology. The fact is that endocan is an important biomodulator that presents in complicated pregnancies, probably due to the potential role of regulating insulin resistance, like the association shown with T2DM formerly.…”

Section: Discussionmentioning

confidence: 99%

Is maternal serum endocan level a novel marker in gestational diabetes mellitus?

Yıldız

Gencer

Timur

et al. 2023

J of Obstet and Gynaecol

View full text Add to dashboard Cite

AimTo determine whether there was a significant difference between serum endocan levels of pregnant women with and without gestational diabetes mellitus (GDM).MethodsA total of 90 pregnant women, 45 with gestational diabetes and 45 healthy pregnant women, between 24 and 28 gestational weeks, were included in this prospective case–control study. The pregnant women were screened for gestational diabetes using a two‐step protocol. Serum endocan levels were measured using a commercially available enzyme‐linked immunosorbent assay (ELISA) kit. A p‐value of <0.05 was considered statistically significant.ResultsSerum endocan level was significantly higher in the GDM group than in healthy controls (168.46 ± 160.6 vs. 105.66 ± 26.52 pg/mL, respectively; p < 0.001). Serum endocan concentrations were positively correlated with the results of 50 g oral glucose challenge test (GCT) (p < 0.001). Receiver operating characteristic curve analysis showed that endocan with a cut‐off point of 133.9 ng/dL indicated women with GDM with a sensitivity of 55.6% and specificity of 88.9% (area under the curve [AUC]: 0.737, 95% CI: 0.634–0.824). The overall differential performance of endocan according to the GDM groups was determined as 73.7% (p < 0.001). Maternal serum endocan level was positively correlated with fasting glucose, postprandial glucose, and glycated hemoglobin (HbA1c) (p < 0.001).ConclusionsElevated endocan levels in gestational diabetes were correlated with fasting glucose, postprandial glucose, HbA1c, and oral glucose tolerance test (OGTT) results. Despite the low sensitivity of 55.6% and the high specificity of 88.9%, we found a high differential performance rate indicating that serum endocan levels were important for the pathophysiology of GDM and should be investigated for the possibility of being a novel marker in larger populations.

show abstract

“…In CKD, elevated levels of endocan were observed compared to the control group, and the concentration of endocan positively correlated with the CKD stage while negatively correlated with the estimated glomerular filtration rate [6]. Additionally, higher levels of endocan were noted in CKD patients with cardiovascular disease (CVD) than in those without CVD [36]. In hemodialysis, patients with higher endocan levels were found to have more frequent CV events, lower BMI, and lower serum TG and albumin levels [18].…”

Section: Discussionmentioning

confidence: 99%

Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients

Lin,

Hsu,

Wang

et al. 2023

JCM

View full text Add to dashboard Cite

Endocan, a pro-inflammatory cytokine and pro-angiogenic factor, is a marker of endothelial dysfunction and has been proven to correlate with cardiovascular disease. In hemodialysis (HD) patients, cardiovascular disease is the major cause of mortality. Our study aimed to investigate the relationship between serum endocan and all causes of mortality in HD patients. A total of 103 patients, aged over 20 years old and undergoing HD for more than 3 months, were included and followed for 36 months. Mortality events, serum endocan, biochemical data, body mass index, systolic and diastolic blood pressure, baseline characteristics, and the use of antihypertensive and lipid-lowering drugs were recorded. In our study, a total of 26 deaths (25.2%) occurred. Hemodialysis patients with diabetes mellitus, older age, higher serum endocan, and lower creatinine and albumin levels had a higher risk of mortality. Adjusting for prognostic variables, HD patients with higher serum endocan (p = 0.010) and lower serum creatinine (p = 0.034) demonstrated significantly higher all-cause mortality. In our study, increased endocan and lower creatinine are associated with all-cause mortality in HD patients. Serum endocan levels could serve as a biomarker for a high mortality risk in HD patients.

show abstract

Prognostic and Diagnostic Value of Endocan in Kidney Diseases

Cited by 8 publications

References 76 publications

Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4

Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4

Is maternal serum endocan level a novel marker in gestational diabetes mellitus?

Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients

Contact Info

Product

Resources

About